Ligand Pharmaceuticals
LGND
326 hedge funds and large institutions have $4.07B invested in Ligand Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 60 funds opening new positions, 95 increasing their positions, 129 reducing their positions, and 26 closing their positions.
131% more first-time investments, than exits
New positions opened: 60 | Existing positions closed: 26
71% more funds holding in top 10
Funds holding in top 10: 7 → 12 (+5)
20% more capital invested
Capital invested by funds: $3.38B → $4.07B (+$685M)
9% more funds holding
Funds holding: 298 → 326 (+28)
0.08% more ownership
Funds ownership: 116.19% → 116.27% (+0.08%)
25% less call options, than puts
Call options by funds: $9.61M | Put options by funds: $12.8M
26% less repeat investments, than reductions
Existing positions increased: 95 | Existing positions reduced: 129
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$57.9M |
| 2 |
Renaissance Technologies
New York
|
+$49.9M |
| 3 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
+$31.9M |
| 4 |
Two Sigma Investments
New York
|
+$23.7M |
| 5 |
Two Sigma Advisers
New York
|
+$21.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCMLC
Cardinal Capital Management LLC (Connecticut)
Greenwich,
Connecticut
|
-$34.1M |
| 2 |
William Blair Investment Management
Chicago,
Illinois
|
-$33.4M |
| 3 |
DMK
David M. Knott
|
-$33.3M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$28.5M |
| 5 |
CLM
ClearBridge LLC (Maryland)
Baltimore,
Maryland
|
-$18.3M |
LGND Hedge Fund Activity: Q1 2018 in Review
326 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q1 2018, worth a combined $4.07B — up 20% from $3.38B a quarter earlier.
Buyers outnumbered sellers: 60 funds opened new LGND positions and 26 closed out — a net gain of 34 holders — while 95 added to existing stakes and 129 trimmed.
The largest buyer was Ameriprise, adding an estimated $57.9M. The largest seller was Cardinal Capital Management LLC (Connecticut), cutting an estimated $34.1M.
- 326 institutional investors held Ligand Pharmaceuticals (LGND) as of Q1 2018, up from 298 in Q4 2017.
- Funds reported $4.07B of Ligand Pharmaceuticals stock for Q1 2018, up 20% quarter-over-quarter.
- 60 funds opened new Ligand Pharmaceuticals positions in Q1 2018 and 26 closed out, a net change of +34 holders.
- The largest Ligand Pharmaceuticals buyer in Q1 2018 was Ameriprise, an estimated $57.9M added.
- The largest Ligand Pharmaceuticals seller in Q1 2018 was Cardinal Capital Management LLC (Connecticut), an estimated $34.1M sold.
Based on aggregated 13F filings for Q1 2018.